A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Clinical trial NCT07535840 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07535840
Sponsor: Tongji Hospital
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

HCC - Hepatocellular Carcinoma TP53 Gene Mutation Unresectable Resistant Cancer

Start date: 2026-05-01
Primary completion: 2026-12-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.